Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025) - Archive ouverte HAL Access content directly
Journal Articles Antimicrobial Agents and Chemotherapy Year : 2020

Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025)

(1) , (1) , (1) , (1) , (1) , (1) , (1) , (1) , (1, 2, 3) , (1, 2, 3) , (1)
1
2
3

Abstract

Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective concentration (EC 50 ) of 0.46 ± 0.04 μM. Alisporivir inhibited a postentry step of the SARS-CoV-2 life cycle. These results justify rapidly conducting a proof-of-concept phase 2 trial with alisporivir in patients with SARS-CoV-2 infection.

Dates and versions

inserm-03258933 , version 1 (12-06-2021)

Identifiers

Cite

Laurent Softic, Rozenn Brillet, François Berry, Nazim Ahnou, Quentin Nevers, et al.. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). Antimicrobial Agents and Chemotherapy, 2020, 64 (7), pp.e00876-20. ⟨10.1128/AAC.00876-20⟩. ⟨inserm-03258933⟩

Collections

INSERM IMRB UPEC
29 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More